<DOC>
	<DOCNO>NCT00025285</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth cancer stop blood flow tumor . Combining thalidomide chemotherapy may kill tumor cell effective treatment stage IIIB stage IV non-small cell lung cancer . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus thalidomide treating patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Thalidomide Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate duration response patient stage IIIB IV non-small cell lung cancer treat carboplatin , irinotecan , thalidomide . - Determine progression-free overall survival patient treat regimen . - Evaluate toxicity profile regimen patient . OUTLINE : Patients receive carboplatin IV 30 minute day 1 irinotecan IV 90 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients stable responsive disease receive 6 course therapy . Patients also receive oral thalidomide daily begin day 1 continue disease progression . Patients follow every 3 month disease progression every 6 month thereafter . PROJECTED ACCRUAL : A total 39-70 patient accrue study within 14 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB ( malignant pleural effusion ) stage IV nonsmall cell lung cancer Squamous cell carcinoma Basaloid carcinoma Adenocarcinoma Bronchoalveolar carcinoma Adenosquamous carcinoma Large cell carcinoma Large cell neuroendocrine carcinoma Giant cell carcinoma Sarcomatoid carcinoma Nonsmall cell carcinoma otherwise specify Measurable disease At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan The following lesion consider nonmeasurable : Bone lesion Leptomeningeal disease Ascites Pleural pericardial effusion Abdominal mass unconfirmed image technique Cystic lesion Previously irradiate brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective contraception 4 week prior , , least 4 week thalidomide No prior seizures No concurrent prior malignancy within past 5 year except inactive nonmelanoma skin cancer carcinoma situ cervix No serious medical psychiatric illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except steroid adrenal failure , hormone noncancerrelated condition ( e.g. , insulin diabetes ) intermittent dexamethasone antiemetic Radiotherapy : Prior radiotherapy brain metastasis allow neurologically stable steroid No concurrent palliative radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>